Phreesia(PHR)
Search documents
Phreesia(PHR) - 2024 Q3 - Earnings Call Transcript
2023-12-06 01:04
Phreesia, Inc. (NYSE:PHR) Q3 2024 Earnings Call Transcript December 5, 2023 5:00 PM ET Company Participants Balaji Gandhi - Chief Financial Officer Chaim Indig - Chief Executive Officer Ryan Daniels - William Blair Vishal Patel - Piper Sandler Glen Santangelo - Jefferies Richard Close - Canaccord Genuity Daniel Grosslight - Citi Scott Schoenhaus - KeyBanc Ryan MacDonald - Needham & Company Jeff Garro - Stephens Tom Kelliher - RBC Capital Markets First, I would like to introduce Balaji Gandhi, Phreesia's Chi ...
Phreesia(PHR) - 2024 Q3 - Quarterly Report
2023-12-05 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38977 PHREESIA, INC. (Exact name of registrant as specified in its charter) Delaware 20-2275479 (State or other jurisdiction of incorporation or organization) FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ...
Phreesia(PHR) - 2024 Q2 - Earnings Call Transcript
2023-09-07 01:22
Phreesia, Inc. (NYSE:PHR) Q2 2024 Earnings Conference Call September 6, 2023 5:00 PM ET | --- | |-------------------------------------------------------------------------------| | | | Chaim Indig - Chief Executive Officer Balaji Gandhi - Chief Financial Officer | | Conference Call Participants | | Ryan Daniels - William Blair | | Jessica Tassan - Piper Sandler | | Joe Vruwink - Baird | | Richard Close - Canaccord Genuity Glen Santangelo - Jefferies | | Scott Schoenhaus - KeyBanc | | Daniel Grosslight - Citi ...
Phreesia(PHR) - 2023 Q2 - Earnings Call Presentation
2023-09-06 20:27
>$3.6B patient payments processed latest twelve months3,4 Patient-centered care • Flexible payment options Phreesia Phreesia Land new clients Grow footprint within existing clients 3 • $610B out-of-pocket spend by 20302 • Improved cash flow and profitability How we make money IN THE OFFICE t + • Proven ability to continuously innovate The Phreesia platform | --- | --- | --- | --- | --- | --- | |-----------|-------------------------------|-----------------------------------|-------------------------------|-- ...
Phreesia(PHR) - 2024 Q2 - Quarterly Report
2023-09-06 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38977 PHREESIA, INC. (Exact name of registrant as specified in its charter) Delaware 20-2275479 (State or other jurisdiction of ...
Phreesia(PHR) - 2024 Q1 - Earnings Call Transcript
2023-06-01 00:17
I think thatÂ's the plan. Yes. Chaim Indig Balaji Gandhi Balaji Gandhi And weÂ'll go next now to Robert Simmons at D.A. Davidson. Balaji Gandhi All right. Just checking. Everyone always complains that I have crappy phone service. So I just assumed it was us. Operator Operator Chaim Indig We go next now to Ryan MacDonald at Needham. John Ransom Balaji Gandhi Okay. So thatÂ's a perfect lead into my next question. You saw that huge volume quarter. How much of that was a function of just utilization improvement ...
Phreesia(PHR) - 2024 Q1 - Quarterly Report
2023-05-31 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38977 PHREESIA, INC. (Exact name of registrant as specified in its charter) Delaware 20-2275479 (State or other jurisdiction of ...
Phreesia(PHR) - 2023 Q4 - Earnings Call Transcript
2023-03-23 03:09
Financial Data and Key Metrics - Revenue in Q4 was $77 million, up 32% YoY, marking the eighth consecutive quarter of over 30% YoY revenue growth [9] - Average number of healthcare services clients in Q4 was 3,140, up 36% YoY, with 158 clients added sequentially [10] - Total revenue per average healthcare services client was $24,390, down 3% YoY and 1% sequentially, driven by client growth outpacing revenue growth in subscription and payment processing [11] - Subscription-related services revenue grew 35% YoY, payment processing revenue grew 23% YoY, and network solutions revenue grew 36% YoY [11] - For fiscal 2024, revenue is expected to be in the range of $353 million to $356 million, implying 26% to 27% growth over fiscal 2023 [12] - Adjusted EBITDA for fiscal 2024 is expected to be in the range of negative $65 million to negative $60 million, showing continued improvement toward profitability [12] Business Line Data and Key Metrics - Healthcare services revenue, combining subscription and related services with payment processing, grew 31% YoY in Q4 [10] - Network solutions revenue saw strong growth, driven by client focus on ROI and the effectiveness of the company's team [22] - The company facilitated over 120 million visits in fiscal 2023, up 20% YoY, with healthcare services client growth slightly outpacing visit growth [38] Market Data and Key Metrics - The company expects a sequential increase in average healthcare services clients in Q1 of fiscal 2024, similar to the 158-client increase seen in Q4 of fiscal 2023 [13] - The company remains comfortable with its ability to finance fiscal 2025 targets, including reaching $500 million in annualized revenue and achieving adjusted EBITDA profitability [14] Company Strategy and Industry Competition - The company is focused on delivering durable and profitable growth, with a strong emphasis on ROI and client value [22] - The company is investing in product development and new markets, with a goal of returning to adjusted EBITDA profitability in fiscal 2025 [14] - The company is well-positioned to capitalize on the growing demand for healthcare automation and patient engagement solutions [22] Management Commentary on Operating Environment and Future Outlook - Management highlighted the strong performance of the network solutions segment, attributing it to client focus on ROI and the effectiveness of the company's team [22] - The company is optimistic about its ability to achieve fiscal 2025 targets, including reaching $500 million in annualized revenue and achieving adjusted EBITDA profitability [14] - Management emphasized the importance of maintaining a culture of ownership and stewardship of capital, which has contributed to the company's strong financial performance [49] Other Important Information - The company announced a CFO transition, with Balaji Gandhi taking over as CFO on March 24, 2023 [6][7] - The company introduced a new key metric, total revenue per average healthcare services client, which was $24,390 in Q4 [11] Q&A Session Summary Question: Growth in Network Solutions Segment - The company attributed strong growth in the network solutions segment to client focus on ROI and the effectiveness of its team [22] - Management expects continued growth in this segment, driven by client demand for ROI-focused solutions [22] Question: Outlook for Fiscal 2024 - The company expects revenue growth of 26% to 27% in fiscal 2024, driven by client growth and stable revenue per client [12][35] - Management highlighted the importance of maintaining operating leverage and achieving adjusted EBITDA profitability in fiscal 2025 [14] Question: Payment Processing Revenue - Payment processing revenue grew 23% YoY in Q4, with management expecting stable growth in fiscal 2024 [11][35] - The company is focused on improving payment processing margins and expects to see improvement as it scales [95] Question: Social Determinants of Health Screening Tool - The company provides social determinants of health modules as part of its package but does not currently monetize this offering [42] - Management believes this is the right thing to do for clients and patients, and there are no plans to charge for this service [42] Question: EBITDA Performance and Guidance - Management discussed the factors that contributed to better-than-expected EBITDA performance in fiscal 2023, including improved productivity and cost management [46][48] - The company expects continued improvement in EBITDA, with a goal of achieving profitability in fiscal 2025 [14] Question: New Metric - Total Revenue per Average Healthcare Services Client - The company introduced this metric to provide a more comprehensive view of revenue performance across subscription, payment processing, and network solutions [52] - Management expects this metric to fluctuate based on the contribution of different revenue streams in any given quarter [52] Question: Long-Term Growth and Client Retention - The company is focused on both client acquisition and expansion, with a strong emphasis on delivering value to existing clients [50][52] - Management highlighted the importance of cross-selling and upselling to drive long-term growth [100] Question: R&D Investments and Product Development - The company is investing in R&D to drive product innovation and expand into new markets [122] - Management expects R&D expenses to grow in line with revenue, contributing to long-term operating leverage [124] Question: Payer and Referral Management Growth - The company is seeing early success in the payer space, with the first enrollment period for MemberConnect performing better than expected [26][27] - Management is optimistic about the growth potential of these newer vectors but is still in the learning phase [27] Question: Commercial Team and Cross-Selling - The company has separate teams for new client acquisition and client expansion, both of which are performing well [92] - Management is focused on cross-training and enabling the commercial team to sell the full suite of solutions [100] Question: Payment Fees per Provider Client - Payment fees per provider client declined 10% YoY in Q4, driven by a mix of client types [119] - Management expects this metric to stabilize and return to more normalized growth in fiscal 2024 [120] Question: Capital Allocation and Acquisitions - The company is committed to being a good steward of capital and will consider acquisitions if they align with strategic goals and deliver strong returns [149] - Management emphasized the importance of acquiring great capabilities rather than just good deals [149] Question: Life Sciences Growth - Growth in the life sciences segment is being driven by greater wallet share from existing clients, new client acquisitions, and strong execution [151] - The company is focused on delivering value to life sciences clients and expanding its footprint in this market [151] Question: Hospital Market Expansion - The company has seen success in various hospital segments, including children's hospitals, community hospitals, and regional hospitals [170] - Management is focused on delivering value to hospitals through automation and improved workflows [170]
Phreesia(PHR) - 2023 Q4 - Annual Report
2023-03-22 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ Commission File Number: 001-38977 PHREESIA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 20-2275479 (State or Other Jurisdiction of Inc ...
Phreesia(PHR) - 2023 Q3 - Earnings Call Transcript
2022-12-09 01:37
Phreesia, Inc. (NYSE:PHR) Q3 2023 Earnings Conference Call December 8, 2022 5:00 PM ET Company Participants Balaji Gandhi - SVP, IR Chaim Indig - CEO & Co-Founder Randy Rasmussen - CFO Conference Call Participants Anne Samuel - JPMorgan Ryan Daniels - William Blair Richard Close - Canaccord Genuity Jessica Tassan - Piper Sandler Stephanie Davis - SVB Securities Glen Santangelo - Jefferies Daniel Grosslight - Citi John Ransom - Raymond James Scott Schoenhaus - KeyBanc Joe Vruwink - Baird Ryan MacDonald - Nee ...